11/18
01:19 pm
pmvp
PMV Pharmaceuticals (NASDAQ:PMVP) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
PMV Pharmaceuticals (NASDAQ:PMVP) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/12
08:00 am
pmvp
PMV Pharmaceuticals Reports Third Quarter 2025 Financial Results and Corporate Highlights
Medium
Report
PMV Pharmaceuticals Reports Third Quarter 2025 Financial Results and Corporate Highlights
11/7
01:15 am
pmvp
PMV Pharmaceuticals (NASDAQ:PMVP) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
PMV Pharmaceuticals (NASDAQ:PMVP) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
10/24
11:39 am
pmvp
PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation
Low
Report
PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation
10/13
04:21 pm
pmvp
PMV Pharmaceuticals to Present Rezatapopt Pivotal Phase 2 Initial Analysis and Natural History Study Results at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics [Yahoo! Finance]
Medium
Report
PMV Pharmaceuticals to Present Rezatapopt Pivotal Phase 2 Initial Analysis and Natural History Study Results at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics [Yahoo! Finance]
10/13
04:01 pm
pmvp
PMV Pharmaceuticals to Present Rezatapopt Pivotal Phase 2 Initial Analysis and Natural History Study Results at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Medium
Report
PMV Pharmaceuticals to Present Rezatapopt Pivotal Phase 2 Initial Analysis and Natural History Study Results at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
9/10
07:24 am
pmvp
PMV Pharmaceuticals Announces Promising Rezatapopt Monotherapy Interim Data From PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation [Yahoo! Finance]
High
Report
PMV Pharmaceuticals Announces Promising Rezatapopt Monotherapy Interim Data From PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation [Yahoo! Finance]
9/10
07:00 am
pmvp
PMV Pharmaceuticals Announces Promising Rezatapopt Monotherapy Interim Data From PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation
High
Report
PMV Pharmaceuticals Announces Promising Rezatapopt Monotherapy Interim Data From PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation